We evaluated the feasibility of collecting peripheral blood progenitor cells (PBPC) in @entity1 with @entity3052 ( @entity3052 ) following two cycles of induction chemotherapy with @entity8779 , @entity2592 and @entity2879 (ICE), and one cycle of consolidation therapy with high-dose @entity2592 and @entity2664 (HAM). Thirty-six @entity1 of the multicentre treatment trial @entity3052 HD93 were enrolled in this study, and a sufficient number of PBPC was harvested in 30 (83%). Individual peak concentrations of @entity2280 + cells in the blood varied (range 13.1-291.5/microl; median 20.0/microl). To reach the target quantity of 2.5 x 10(6) @entity2280 + cells/kg, between one and six (median two) leukaphereses (LP) were performed. The LP products contained between 0.2 x 10(6) and 18.9 x 10(6) @entity2280 + cells/kg (median 1.2 x 10(6)/kg). Multivariate analysis showed that the white blood cell count prior to HAM and the time interval from the start of HAM therapy to reach an unsupported platelet count > 20 x 10(9)/l were predictive for the peak value of @entity2280 + cells in the blood during the @entity1261 stimulated haematological recovery. In 16 @entity1 an intraindividual comparison was made between bone marrow (BM) and PBPC grafts. Compared to BM grafts, PBPC grafts contained 14-fold more MNC, 5-fold more @entity2280 + cells and 36-fold more CFU-GM. A @entity2280 + subset analysis showed that blood-derived @entity2280 + cells had a more immature phenotype as indicated by a lower mean fluorescence intensity for HLA-DR and @entity3053 . In addition, the proportion of @entity2280 +/ @entity5399 + cells tended to be greater in the PBPC grafts. The data indicate that sufficient PBPC can be collected in the majority of @entity1 with @entity3052 following intensive double induction and first consolidation therapy with high-dose @entity2592 and @entity2664 .

Successful collection of peripheral blood progenitor cells in XXXX with @entity3052 following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose @entity2592 and @entity2664 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF'] @entity8779 :: ('MESH:D015255', 'Chemical') :: ['idarubicin'] @entity2664 :: ('MESH:D008942', 'Chemical') :: ['mitoxantrone'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukaemia', 'AML'] @entity5399 :: ('7070', 'Gene') :: ['Thy-1'] @entity3053 :: ('952', 'Gene') :: ['CD38'] @entity2280 :: ('947', 'Gene') :: ['CD34']
@entity1 :: (9606,Species) :: ['patients']
